Cancer drug repurposed in fight against Alzheimer's
NCT ID NCT02947893
Summary
This study tested whether low daily doses of nilotinib, a drug used for leukemia, could be safe and potentially slow Alzheimer's disease progression. Thirty-seven people with mild to moderate Alzheimer's took either the drug or a placebo pill for six months. Researchers measured safety and looked for changes in brain proteins linked to Alzheimer's to see if the drug had any effect.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20057, United States
Conditions
Explore the condition pages connected to this study.